Company Overview and News

 
Helix TCS Inc. to Bolster Canadian Presence in Anticipation of Recreational Legalization in October

2018-09-13 globenewswire
Greenwood Village, CO, Sept. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Helix TCS, Inc. (OTCQB: HLIX) (the “Company”), a premier provider of integrated operating environment solutions for the legal cannabis industry, today announced that the Company has formed an internal committee and engaged Alixe Cormick and Venture Law Corporation as Canadian counsel.
JGLDD HLIX

 
Helix TCS Inc. Releases Pro-Forma Financial Results for Recent Merger with BioTrackTHC

2018-08-15 globenewswire
GREENWOOD VILLAGE, CO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB: HLIX) (the “Company”), is pleased to announce that it has released its 8-K/A disclosing the pro-forma financial statements for the Company’s previously reported merger with Bio-Tech Medical Software, Inc. dba BioTrackTHC (“BioTrack”), which closed on June 1, 2018.
JGLDD HLIX

 
HLIX / Helix TCS, Inc. QUARTERLY REPORT (Quarterly Report)

2018-08-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549<
HLIX

 
BioTrackTHC to Present and Exhibit in San Jose

2018-07-19 globenewswire
GREENWOOD VILLAGE, CO, July 19, 2018 (GLOBE NEWSWIRE) -- BioTrackTHC, a Helix TCS, Inc. (OTCQB: HLIX) company, will be attending the National Cannabis Industry Association’s (NCIA) Cannabis Business Summit and Expo in San Jose, California next week. The company will have team members participating in two lounge discussion sessions focused on cultivation tracking and dispensary point of sale best practices for the future of cannabis business operations.
JGLDD HLIX

5
HLIX / Helix TCS, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-22 fintel.io
Helix TCS, Inc. (OTC:HLIX) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Helix TCS, Inc. (OTC:HLIX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
SGEN JGLDD HLIX

1
HLIX / Helix TCS, Inc. CURRENT REPORT (Current Report)

2018-06-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
HLIX

1
Helix TCS Inc. and BioTrackTHC Close Previously Announced Merger

2018-06-04 globenewswire
GREENWOOD VILLAGE, CO , June 04, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB: HLIX), in conjunction with its strategic capital partner, Rose Capital, is pleased to announce the closing of its previously reported merger with Bio-Tech Medical Software, Inc. dba BioTrackTHC. The merger closed on June 1st. Zachary L. Venegas will continue as the CEO of Helix TCS, Inc., and is to assume the role of Executive Chairman for the combined company.
JGLDD HLIX

1
Helix TCS, Inc. Announces 63% Revenue Growth in Q1 2018

2018-05-16 globenewswire
GREENWOOD VILLAGE, CO. , May 16, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB: HLIX), the leading provider of integrated operating environment solutions for the legal cannabis industry, announced its first quarter 2018 financial results today.
JGLDD HLIX

2

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...